RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide First Quarter 2022 Update on Medical Aesthetic Launch
RVL Pharmaceuticals plc will announce its 2021 Q4 and full-year financial results on March 30, 2022, after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RVL Pharmaceuticals plc will announce its 2021 Q4 and full-year financial results on March 30, 2022, after U.S. market close. The Company will also provide updates on its first-quarter 2022 Medical Aesthetic launch. The conference call with key executives will be held at 4:30 p.m. ET on the same day. RVL is focused on developing products for underserved patient populations, currently commercializing UPNEEQ (oxymetazoline hydrochloride ophthalmic solution), 0.1%. For further details, investors can visit the Company's website.
Positive
- Plans to release significant financial results and product updates.
- Focus on underserved patient populations may lead to strong market demand.
Negative
- None.
Details
News Market Reaction – RVLP
The recorded move for RVLP in the trading session of this news was +1.64%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference call to be held March 30, 2022, at 4:30 p.m. ET --
BRIDGEWATER, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 fourth quarter and full year financial results and provide an update of its first quarter 2022 Medical Aesthetic launch on Wednesday, March 30, 2022, after the close of the U.S. financial markets.
Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows:
| Date | Wednesday, March 30, 2022 |
| Time | 4:30 p.m. ET |
| Toll free (U.S.) | (866) 672-5029 |
| International | (409) 217-8312 |
| Conference ID | 4273945 |
| Webcast (live and replay) | www.rvlpharma.com under the “Investor & News” section |
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution),
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.